---
title: "Laekna files HKEX next-day disclosure return disclosing share repurchase for cancellation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292186861.md"
description: "Laekna filed a next-day disclosure return with the HKEX regarding a share repurchase for cancellation. On July 9, the company bought back 50,000 ordinary shares at prices between HKD 6.98 and HKD 7.37, totaling HKD 355,100. As of the filing date, these shares had not yet been cancelled, leaving the issued share count unchanged at 449,331,350."
datetime: "2026-07-09T10:50:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292186861.md)
  - [en](https://longbridge.com/en/news/292186861.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292186861.md)
generator: "portal-rs"
---

# Laekna files HKEX next-day disclosure return disclosing share repurchase for cancellation

-   Laekna repurchased 50,000 ordinary shares on July 9 for cancellation at HKD 6.98–HKD 7.37, paying HKD 355,100. \* Issued share count stayed at 449,331,350; the 50,000 shares were not yet cancelled as of the filing date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260709-12239626), on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Laekna enrolls first patient in China Phase I trial of cancer drug candidate LAE118](https://longbridge.com/en/news/297573070.md)
- [Laekna Starts First-Patient Phase I Trial of LAE118 and Deepens Vasque Bio Alliance](https://longbridge.com/en/news/297576055.md)
- [Hong Kong Food Investment files HKEX next-day return disclosing share buyback for cancellation](https://longbridge.com/en/news/297775695.md)
- [Hong Kong Food Investment files HKEX next-day disclosure return on share buyback cancellation](https://longbridge.com/en/news/297910569.md)
- [ZXZN Qi-House files next-day disclosure return in Hong Kong, share capital rises by 130 million shares](https://longbridge.com/en/news/297756452.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**